Both normal and tumor cells release small frgaments of free circullating DNA (cfDNA) into the bloodstream. The term liquid biopsy describes a non-invasive, highly sensitive and economical method for isolating and detecting those small fragments present in the plasma of patients diagnosed with cancer.
This test identifies 150mutation in 11 of the genes previously associated with;
- Lung Cancer (BRAF, CTNNB1, EGFR, FOXL2, GNAS, KRAS, NRAS, PIK3CA, TP53)
- Colon Cancer (AKT1, BRAF, CTNNB1, EGFR, ERBB2, FBXW, GNAS, KRAS, MAP2K1, NRAS, PIK3CA, SMAD4, TP53 Y APC)
- Breast Cancer (BRCA1 Y BRCA2 with a coverage of 100% of the exonic sequences).
This test consists of collecting 2 tubes of 10ml of blood, this sample will be sent to our laboratory, where we porceed to the insolation of of cfDNA. The sample will then be enriched and analyzed to search for specific somatic cells using mass sequencing thechniques. It also has a detection capacity of the variants analyzed below 0.1% with a sensitivity of 90% and a specificity above 98% using cfDNA analysis from blood plasma samples
► It is fast. We offer results i n Ofrecemos resultados en 25 días.
► Permite analizar marcadores 25 days.
► It offers high sensitivity to detect circulating free DNA (cfDNA) froma the tumor in the plasma.
► Generates results easy to interpret.
► It allows to personalize the treatment and to monitor the progression of the tumor, with a simple blood sample.